Seeking Alpha • May 13

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early

Summary Arbutus Biopharma targets chronic hepatitis B with Imdusiran, addressing a vast, unmet medical need in a 250-million-patient market. Imdusiran showed a 46% functional cure/discontinuation rate in Phase 2a; Phase 2b trials, with Fast Track designation, are expected to start this year. ABUS will receive $190M from a legal settlement, bolstering its $91.5M cash position, but ongoing cash burn means further capital raises are likely. Valuation appears fair at current levels given a 25% probability of success; significant upside depends on positive Phase 2b results and potential acquisition interest. Read the full article on Seeking Alpha

Seeking Alpha • Mar 28

Arbutus Biopharma: A Wing And A Prayer

Summary Arbutus Biopharma just announced another significant restructuring, including layoffs and management changes, to reduce cash burn and streamline operations. The company is now focused on developing its sole drug candidate, imdusiran, which has shown promising early results in treating Hepatitis B. Analysts remain cautiously optimistic, with several maintaining Buy ratings, but the stock's future hinges on imdusiran's success and ongoing patent litigation outcomes. An updated analysis of this clinical-stage biopharma concern follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Jan 30

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Summary Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology. The Capital One and Discover Financial merger should proceed smoothly under new, more business-friendly regulators, offering a lucrative arbitrage opportunity. Cadiz, a water company, is poised for growth as California's water infrastructure issues create demand for its extensive underground water resources and pipeline projects. Burford Capital, a litigation funding company, has a significant opportunity with its Petersen claims against Argentina, bolstered by the country's new pro-market president. Read the full article on Seeking Alpha

Seeking Alpha • Jan 07

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Summary Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-101, with preliminary data expected in the first half of 2025. The global Hepatitis B Virus market size is anticipated to reach $6.65 billion by 2034. Company has a strong cash position, with $130.8 million on hand, sufficient to fund operations into Q4 2026. Read the full article on Seeking Alpha

Seeking Alpha • Jul 05

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Summary Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis B. ABUS is engaged in significant IP litigation with Moderna, Pfizer, and BioNTech over LNP technology used in mRNA vaccines. Positive litigation outcomes could result in substantial financial compensation and enhance ABUS’s IP value. The Company’s strong cash position and promising clinical pipeline support its undervaluation and strong buy rating. Read the full article on Seeking Alpha

Analiz Makalesi • May 23

Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shares have had a really impressive month, gaining 29% after a shaky...

Seeking Alpha • Apr 23

Moderna Investors Should Beware Patent-Dispute Fallout

Summary Moderna's stock rose after positive results from its cancer vaccine trial, but legal issues could lead to a massive judgment against the company. Moderna is facing a patent dispute over its use of lipid nanoparticles technology without proper licensing or compensation. I believe the company's defense, citing an obscure law, is unlikely to hold up in court, and the outcome could result in significant damages. Read the full article on Seeking Alpha

Seeking Alpha • Apr 10

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

Summary Arbutus Biopharma and Roivant won a crucial claims construction ruling in their patent infringement lawsuit against Moderna. The ruling opens the way for a potential total win against Moderna, but uncertainties remain regarding the lawsuit and Arbutus' pipeline. The potential litigation payout could be significant, but the company's expensive pipeline development and cash burn rate are concerns. Read the full article on Seeking Alpha

Analiz Makalesi • Feb 10

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Jan 03

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shares have been powering on, with a gain...

Analiz Makalesi • Nov 09

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Shareholders in Arbutus Biopharma Corporation ( NASDAQ:ABUS ) may be thrilled to learn that the analysts have just...

Analiz Makalesi • Oct 24

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Arbutus Biopharma Corporation's ( NASDAQ:ABUS ) price-to-sales (or "P/S") ratio of 12x might make it look like a sell...

Analiz Makalesi • Apr 26

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analiz Makalesi • Nov 11

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...

Analiz Makalesi • Oct 28

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Sep 12

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Summary Today, we revisit Arbutus Biopharma Corporation for the first time in almost a year. An interesting 'sum of the parts' story seems to be emerging around the company and the stock. An investment analysis follows in the paragraphs below. "I could easily forgive his pride, if he had not mortified mine."― Jane Austen, Pride and Prejudice Today, we put Arbutus Biopharma Corporation (NASDAQ:ABUS) in the spotlight for the first time since mid-September of last year. We concluded that article with the following: We have no investment recommendation on ABUS at this time. We may revisit this name in the future provided upcoming study results are encouraging as it gets to late stage development." The stock is down some 40% since that conclusion, but the stock seems to be building a floor at current trading levels. Given it has been almost a year since we last looked in on Arbutus Biopharma, it is time to circle back on this small biopharma concern. An analysis follows below. Seeking Alpha Company Overview Arbutus Biopharma Corporation is a Philly based clinical-stage biotech firm. The company is focusing its efforts on developing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection as well as developing treatments for Covid. The stock trades for just north of two bucks a share and sports an approximate market cap of just south of $350 million. June Company Presentation Recent Developments: June Company Presentation As we discussed in our last piece on Arbutus, the company is advancing multiple 'shots on goal' within its pipeline. Several notable events have happened around the company since we last visited. In late August, Arbutus garnered a key patent that provides composition of matter patent protection for its lead clinical-stage asset, RNAi therapy AB-729 for chronic hepatitis B virus. In early June, the company initiated a Phase 2a study in conjunction with Vaccitech (VACC). This 40 person trial will evaluate a combination with Vaccitech's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care to treat chronic hepatitis B Virus. June Company Presentation In late July, Arbutus announced that it would continue a phase 2a trial with Assembly Biosciences (ASMB). This study is investigating a combination of AB-729, Assembly's candidate vebicorvir and an inhibitor therapy for the treatment of chronic hepatitis B virus infection. This is despite Assembly discontinuing their developmental efforts around vebicorvir. Late in February, the company's journey took an interesting turn when it and Genevant Sciences filed a lawsuit against Covid vaccine juggernaut Moderna (MRNA). This suit does not request the stoppage of Moderna's vaccine distribution but seeks damages for violation of certain U.S. patents related to the company's COVID-19 shot, MRNA-1273. Then a few weeks later, Acuitas Therapeutics, whose technology has been used in Pfizer (PFE)/BioNTech (BNTX) COVID-19 shot, filed a lawsuit against Arbutus seeking to head off claims that the vaccine violates Arbutus' patents. In December of last year, a federal appeals court upheld a ruling by the U.S. Patent and Trademark Office to not invalidate patents held by Arbutus Biopharma. June Company Presentation The eventual outcome of all this litigation is a 'wildcard' at the moment. An article on Seeking Alpha that came out in mid-December does a good job detailing some potential outcomes. Given how early stage the company's Covid efforts are in the Covid arena, the patent litigation might be the best way to monetize the company's work in this area. Two weeks after the win in federal appeals court, the company announced a licensing agreement and partnership with Qilu Pharmaceutical around AB-729 for hepatitis B in China, Hong Kong, Macau, and Taiwan. This deal provided Arbutus with a nice $40 million upfront payment. The company can also earn another potential $245 million in milestone payouts as well as double-digit tiered royalties up to the low twenties percent on any future commercialization. June Company Presentation As you can see below, the company's pipeline is progressing very slowly and is years away from commercialization. To throw one more nuance into Arbutus's investment thesis, Alnylam Pharmaceuticals, Inc. (ALNY) recently reported positive topline results for their Phase III study of ONPATTRO in patients with ATTR amyloidosis with cardiomyopathy.

Seeking Alpha • Aug 30

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Arbutus Biopharma (NASDAQ:ABUS) said that the U.S. Patent and Trademark Office (USPTO) issued a patent that provides composition of matter patent protection for its RNAi therapy AB-729 for chronic hepatitis B virus. The U.S. patent no. 11,427,823 is expected to provide exclusivity for AB-729 to at least April 2038, the company noted in an Aug. 30 press release. "AB-729 is our lead clinical-stage asset that we believe is capable of being a cornerstone agent in the treatment regimen to provide a functional cure for patients with cHBV," said President and CEO William Collier. Arbutus added that AB-729 is currently in multiple phase 2a studies. ABUS +3.07% to $2.35 premarket Aug. 30

Analiz Makalesi • Aug 06

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...

Seeking Alpha • Jul 20

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Arbutus Biopharma (NASDAQ:ABUS) on Wednesday said its phase 2a hepatitis B virus infection trial with partner Assembly Biosciences (ASMB) evaluating a combination involving drug candidates by both companies would continue, despite ASMB's decision to stop development of its product. ASMB in a separate release said that it would end development of its inhibitor vebicorvir. But ABUS and ASMB, after consultation, plan to continue their phase 2a trial investigating a combination of ABUS' RNAi therapeutic AB-729, ASMB's vebicorvir and an inhibitor therapy for the treatment of chronic hepatitis B virus infection. “While we respect Assembly’s decision to discontinue clinical development of (vebicorvir), we believe that it is premature to make any conclusions about any results in this triple combination clinical trial," said ABUS CEO William Collier. "We intend, in collaboration with Assembly, to continue the clinical trial in order to fully and accurately assess the results," Collier added. ABUS said preliminary data from the mid-stage trial is expected in H2 of this year. Arbutus (ABUS) stock was up 3.1% to $2.65 after hours.

Seeking Alpha • Jun 29

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a triple combination regimen with AB-729; In addition, potential to advance very same drug for oncology use. Pan-coronavirus program is being advanced into IND-enabling studies in 2022, should it go well I expect a phase 1 study to be initiated thereafter. Arbutus had $221.8 million in cash as of March 31, 2022; Enough cash to fund its operations into Q2 of 2024. Arbutus Biopharma Corporation (ABUS) is a great speculative biotech to look into. The reason why I state that is because it just recently released new data at the most recent EASL International Liver Congress for AB-729 for the treatment of patients with Hepatitis B. For starters, AB-729 shown at the conference was impressive in itself. Thus far between 8 and 24 weeks of follow-up, after patients stopped receiving doses of AB-729, there was no evidence of virologic or clinical relapse. This needs to be monitored for longer than 24 weeks, but if these patients continue to maintain such levels for a 1-year or more they could reach a partial of functional cure of Hepatitis B. This is just on the back of AB-729 alone. Which brings me to the next point, which is that there are two key catalysts approaching in the 2nd half of 2022, which I believe could add significant value for the stock. It is because there is data coming which will be released from two triple-combination studies with AB-729. One triple combination is AB-729 with Assembly Biosciences (ASMB) vebicorvir plus Nrtl standard of care therapy and the second one is AB-729 with Nrtl plus short courses of pegylated interferon alfa-2a. With AB-729 alone having achieved such great potential towards a partial/full function cure of chronic hepatitis B, I believe one of these triple combination studies could be even better. As such, the risk/reward with the stock trading around $2.60 per share is quite ideal. Especially, since Vir Biotechnology (VIR) is also using an RNAi drug like AB-729, which, when placed with PEG-IFN-α, achieved a far more substantial Hepatitis B surface antigen ((HBsAg)) decline compared to VIR-2218 alone. I have more confidence in this triple combination since an RNAi drug and PEG-IFN-a seems to have worked well when put together. Based on these two key catalysts approaching, these are the reasons why I believe Arbutus is a great speculative biotech play to look into. AB-729 Data Sheds Light On Ability To Restore HBV-specific T-cells Arbutus Biopharma just recently presented updated results for its AB-729 RNA interference ((RNAi)) drug at the EASL International Liver Congress 2022 this past week. It was shown that AB-729 alone was able to allow patients to achieve robust HBsAg declines. This was observed in both HBeAg + and HBeAg- patients, which is even better. About 16 out of 32 patients (50%) maintained HBsAg levels below 100 IU/mL 24 weeks after their last dose of AB-729. These data show that AB-729 alone is quite strong, which is a solid foundation for the biotech to build upon. However, what I found most intriguing is that the first 5 patients thus far who discontinued both AB-729 plus Nucleoside Analogue ((NA)) therapy had no evidence of virologic or clinical relapse between 8 to 24 weeks of follow up. Why is this crucial? That's because thus far it proves that AB-729 continues to work even after treatment is stopped. One thing to note is that this is preliminary and in order to confirm a partial/full functional cure of Hepatitis B patients will have to be monitored for 1 year or more. Still, AB-729 alone is solid as a cornerstone therapy for the treatment of patients with Hepatitis B. As other patients in this study meet stopping criteria, they too may also be able to stop both AB-729 and NA therapy. From there, Arbutus will monitor all such other patients to see if a virologic or clinical relapse occurs after an extended period of time. How can AB-729 continue to work? This may be possible due to the fact that AB-729 continues to restore HBV specific T-cells and decrease exhausted T-cells. One major problem with this disease is that T-cells are exhausted and are weak to respond to it. With AB-729 alone being able to restore T-cell function, even after treatment is stopped, this may prove to be useful as time goes on. Two Key Catalysts To Watch For 2nd Half Of 2022 As I described above, AB-729 was able to restore HBV-specific T-cells and decrease exhausted T-cells. What comes next? Well, there are going to be two triple-combination studies which will be readout in the 2nd half of 2022. These are important, because they are adding additional drugs which may create a more pronounced response compared to AB-729 alone. The first triple combination would be AB-729 + Assembly's vebicorvir + Nrtl standard of care therapy. A phase 2 randomized open-label clinical trial was initiated back in February of 2021 for this combination. About 60 virologically-suppressed patients with HBeAg negative chronic Hepatitis B Virus ((HBV)) will be recruited. The arms of the study are as follows: AB-729 + Vebicorvir + Nrtl AB-729 + Nrtl Vebicorvir + Nrtl In essence, the triple combination above of AB-729 + vebicorvir + Nrtl must achieve superior outcomes compared to either of the two double combinations alone. Safety will be the most important finding to observe first. After that, other measures will be observed such as HBV DNA, HBV pgRNA and HBsAg levels. The second data readout expected in the 2nd half of 2022 would be a triple-combination study that Arbutus is running itself. This was a phase 2 study that received authorization back in July of 2021. This is a randomized open-label phase 2a study which is testing AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNa-2a in patients with chronic Hepatitis B. About 40 stably NA-suppressed HBeAg negative non-cirrhotic CHB patients are being recruited. Patients are to be given 60 mg of AB-729 every 8 weeks for a total of 24 weeks. After that, patients will be randomized into different dosing groups. The bottom line is that the triple combination of AB-729 + NA + weekly Peg-IFNa-2a will be compared to NA + weekly Peg-IFNa-2a. The goal is to see if the triple combination of AB-729 has a more pronounced effect on reducing HBsAg and other measures in these Hepatitis B patients. I have more confidence in this triple-combination and it is for one primary reason. That reason being, is that Vir Biotechnology already established proof of concept of using an RNAi drug together with Peg-IFN-a. What was proven exactly? Adding an RNAi drug with an immunomodulatory agent pegylated interferon alfa, resulted in potentially more than additive declines in HBsAg. This leads me to believe that since AB-729 is not only an RNAi drug like VIR-2218 but with it being added to Peg-IFNa-2a and Nrtl, that it should also achieve such an additive decline in HBsAg when data is readout. This remains to be seen, but since some proof of concept has been established from Vir, this is why I have more confidence for this triple-combination from Arbutus Biopharma compared to the other one. Financials According to the 10-Q SEC Filing, Arbutus Biopharma had cash, cash equivalents and investments in marketable securities of $221.8 million as of March 31, 2022. A big reason for the influx of cash is that it received $40 million as an upfront payment from Qilu Pharmaceutical Co., Ltd. due to technology transfer and license agreement for AB-729 in the greater China area. Additional funds coming in were a $15 million equity investment from Qilu and about 0.3 million of net proceeds from the issuance of common shares under Arbutus' ATM offering program. The biotech believes that it has sufficient cash to fund its operations into Q2 of 2024. This is very good for investors, because I see no need to raise cash again until the end of 2023. Until then, it has several trial readouts to report anyway. The two notable trial data readouts are from the triple combination studies with AB-729 I have described above. Both of which are expected to be readout in the 2nd half of 2022. Risk To Business The two biggest risks for Arbutus Biopharma would be the upcoming data readouts of the triple-combination studies for AB-729. Even though Vir Biotechnology established proof of concept using its RNAi drug VIR-2218 together with Peg-IFN-a, there is no guarantee that Arbutus will be able to do the same with its drug AB-729. The other risk would be the other triple-combination study noted above of AB-729 with vebicorvir. The hope is that AB-729 being added with vebicorvir + Nrtl would have a more pronounced effect on reducing HBsAg but this remains to be seen. If such a finding is achieved whereby HBsAg is reduced in a superior fashion, then I expect both the stock of Arbutus biopharma and partner Assembly Biosciences to rise significantly.

Analiz Makalesi • Jun 15

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • May 11

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...

Analiz Makalesi • Mar 08

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...

Seeking Alpha • Mar 07

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022. Results from the phase 1a/1b study using AB-729 for Hep B from multiple cohorts are expected at a medical conference in 2022. Results from the phase 1 study using AB-836 for the treatment of patients with Hepatitis B are expected in the 1st half of 2022. Patent litigation against Moderna for patent infringement dealing with its Covid-19 vaccine may possibly bring in revenue for Arbutus/Genevant should a deal be reached or successful litigation in court.

Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	4/6
Finansal Sağlık	5/6
Temettüler	0/6

Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$4.37
52 Haftanın En Yüksek Seviyesi	US$5.10
52 Haftanın En Düşük Seviyesi	US$3.04
Beta	0.62
1 Aylık Değişim	-5.00%
3 Aylık Değişim	3.07%
1 Yıllık Değişim	37.85%
3 Yıllık Değişim	70.70%
5 Yıllık Değişim	57.19%
Halka arzdan bu yana değişim	-37.93%

	ABUS	US Biotechs	US Pazar
7D	1.4%	-3.0%	-0.3%
1Y	37.9%	32.9%	26.7%

ABUS volatility
ABUS Average Weekly Movement	5.9%
Biotechs Industry Average Movement	10.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

ABUS temel i̇stati̇sti̇kler
Piyasa değeri	US$829.66m
Kazançlar(TTM)	US$160.72m
Gelir(TTM)	US$191.45m

ABUS gelir tablosu (TTM)
Gelir	US$191.45m
Gelir Maliyeti	US$20.40m
Brüt Kâr	US$171.04m
Diğer Giderler	US$10.32m
Kazançlar	US$160.72m

Hisse başına kazanç (EPS)	0.81
Brüt Marj	89.34%
Net Kâr Marjı	83.95%
Borç/Özkaynak Oranı	1.3%

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/20 14:10
Gün Sonu Hisse Fiyatı	2026/05/20 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

Analist	Kurum
David Dean	ATB Cormark Historical (Cormark Securities)
David Martin	Bloom Burton & Co.
Madhu Kumar	B. Riley Securities, Inc.

Arbutus Biopharma (ABUS) Hisse Özeti

Ödüller

Risk Analizi

Arbutus Biopharma Corporation Rakipler

XOMA Royalty

Rigel Pharmaceuticals

Abeona Therapeutics

ADMA Biologics

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Revenue and earnings growth

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early

Arbutus Biopharma Corporation Receives U.S. FDA Fast Track Designation For Imdusiran For The Treatment Of Chronic Hepatitis B

Arbutus Biopharma Corporation, Annual General Meeting, May 26, 2026

Consensus revenue estimates increase by 123%

Recent updates

New major risk - Revenue and earnings growth

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early

Arbutus Biopharma Corporation Receives U.S. FDA Fast Track Designation For Imdusiran For The Treatment Of Chronic Hepatitis B

Arbutus Biopharma Corporation, Annual General Meeting, May 26, 2026

Consensus revenue estimates increase by 123%

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Arbutus Biopharma Corporation Announces Functional Cure Achievements in Phase 2A Clinical Trials of Imdusiran

The Board of Appeal of the European Patent Office Revokes Arbutus Biopharma Corporation's European Patent EP 2279254

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Arbutus Biopharma Corporation Announces Additional Analysis of Imdusiran Clinical Data

Arbutus Biopharma Corporation Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2025

Arbutus Biopharma Corporation Announces Appointment of Dr. Harry Janssen to Scientific Advisory Board

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Arbutus Biopharma Corporation Announces Board Changes

High number of new and inexperienced directors

Arbutus Launches a New Scientific Advisory Board

Arbutus Biopharma Corporation Presents Clinical Trial Data from Its Two HBV Assets, Imdusiran and AB-101, At the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus Biopharma Corporation, Annual General Meeting, May 21, 2025

Arbutus Biopharma: A Wing And A Prayer

Arbutus Biopharma Corporation Announces CFO Changes, Effective from March 28 2025

Roivant Sciences Announces Resignation and Replacement of Directors at Arbutus Biopharma

Arbutus Biopharma Corporation Announces CEO Changes

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Consensus revenue estimates fall by 12%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arbutus Biopharma Corporation to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Arbutus Biopharma Corporation to Report Q2, 2024 Results on Aug 01, 2024

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial

Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201)

Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders

Whitefort Capital Management Engages with Arbutus Biopharma

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024

Moderna Investors Should Beware Patent-Dispute Fallout

Arbutus Biopharma Corporation to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Corporation, Annual General Meeting, May 22, 2024

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

Consensus revenue estimates decrease by 11%

Consensus revenue estimates fall by 28%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arbutus Biopharma Corporation to Report Q4, 2023 Results on Feb 29, 2024

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Arbutus Biopharma Corporation Announces CEO Changes

Third quarter 2023 earnings: EPS misses analyst expectations

Arbutus Biopharma Corporation Announces President Changes

Arbutus Biopharma Corporation to Report Q3, 2023 Results on Nov 07, 2023

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101

Consensus revenue estimates decrease by 11%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arbutus Biopharma Corporation to Report Q2, 2023 Results on Aug 03, 2023

Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors